{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alpha1+Anti-Trypsin+Deficiency&page=2",
    "query": {
      "condition": "Alpha1 Anti-Trypsin Deficiency",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Alpha1+Anti-Trypsin+Deficiency&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:14:00.658Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00005098",
      "title": "Study of Genotype and Phenotype in Patients With Alpha 1-Antitrypsin Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "1999-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005098"
    },
    {
      "nct_id": "NCT05899673",
      "title": "An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazirsiran Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2023-08-08",
      "completion_date": "2033-05-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 5,
      "location_summary": "La Jolla, California • Redwood City, California • Gainesville, Florida + 2 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05899673"
    },
    {
      "nct_id": "NCT02168686",
      "title": "Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "ADVM-043",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Adverum Biotechnologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2017-11-28",
      "completion_date": "2019-08-29",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • Charleston, South Carolina",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168686"
    },
    {
      "nct_id": "NCT02810327",
      "title": "Alpha-1 Carrier Genomics Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alpha-1 Antitrypsin Deficiency",
        "Emphysema",
        "COPD",
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Genetic Sequencing",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2015-02",
      "completion_date": "2017-04",
      "has_results": true,
      "last_update_posted_date": "2019-07-22",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02810327"
    },
    {
      "nct_id": "NCT01319331",
      "title": "The Effects of Alpha-1 Antitrypsin (AAT) on the Progression of Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Alpha 1-Antitrypsin (AAT, Aralast NP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "6 Years to 45 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-10",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2017-03-24",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01319331"
    },
    {
      "nct_id": "NCT06512454",
      "title": "A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alpha1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2024-09-25",
      "completion_date": "2032-04-06",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06512454"
    },
    {
      "nct_id": "NCT06505603",
      "title": "PiMZ Longitudinal Cohort (PiMZ Logic)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency",
        "Emphysema or COPD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2025-05-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06505603"
    },
    {
      "nct_id": "NCT01669421",
      "title": "Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1 Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Alpha-1 Antitrypsin (human)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Campos, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2012-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2019-05-08",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669421"
    },
    {
      "nct_id": "NCT03945292",
      "title": "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alpha 1-Antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "Fazisiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-08-07",
      "completion_date": "2023-09-18",
      "has_results": true,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 16,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03945292"
    },
    {
      "nct_id": "NCT02722304",
      "title": "Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Alpha1-antitrypsin Deficiency"
      ],
      "interventions": [
        {
          "name": "ARALAST NP 60 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ARALAST NP 120 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLASSIA 60 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLASSIA 120 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Human Albumin 2%",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2016-11-02",
      "completion_date": "2018-09-14",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-05-22T08:14:00.658Z",
      "location_count": 14,
      "location_summary": "Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722304"
    }
  ]
}